Detalhe da pesquisa
1.
Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants.
N Engl J Med
; 386(9): 837-846, 2022 03 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35235726
2.
Nirsevimab for Prevention of RSV in Term and Late-Preterm Infants.
N Engl J Med
; 388(16): 1533-1534, 2023 04 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-37018470
3.
Infants Receiving a Single Dose of Nirsevimab to Prevent RSV Do Not Have Evidence of Enhanced Disease in Their Second RSV Season.
J Pediatric Infect Dis Soc
; 13(2): 144-147, 2024 Feb 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-38219024
4.
Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials.
Lancet Child Adolesc Health
; 7(3): 180-189, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36634694